echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Jiangsu pharmaceutical companies into the 3 billion injections! AstraZenetas half-insured?

    Jiangsu pharmaceutical companies into the 3 billion injections! AstraZenetas half-insured?

    • Last Update: 2020-10-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, the official website of the State Drug Administration shows that Jiangsu Wu Traditional Chinese Medicine Group Co., Ltd. Suzhou Pharmaceutical Factory's injection of Esso melazole sodium was approved. according to
    meters of intranet data, in 2019 China's public medical institutions terminal Esomerazole (Esso melanzoa) injection sales exceeded 3 billion yuan, of which AstraZeneone market share of 51.48 percent, ranked first.
    data show that the product is a new generation of clinical acid suppressor products, with fast, powerful, long-lasting, small individual differences and so on, used when oral therapy is not applicable, gastroesophageal reflow disease (GERD) alternative therapy;
    In recent years, China's public medical institutions terminal Esomerazo (Esso meprazole) injection sales (units: 100 million yuan) Source: Minet China's public medical institutions terminal competition pattern Minet data show that in recent years in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal Esomerazole injections are growing at a rate of more than 10%, with sales exceeding 3 billion yuan in 2019, with AstraZeneone leading with 51.48 percent of the market, followed by Zhengda Tianqing Pharmaceutical Group with 34.14 percent.
    source: One-click retrieval is worth noting that AstraZeneta's market share has declined rapidly in recent years, from its exclusive market in 2015 to 72.95 per cent in 2017 and to 51.48 per cent in 2019.
    in terms of consistency evaluation, the product has not yet been approved by enterprises.
    source: official website of the State Drug Administration, Mi net database.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.